Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

China flag China · Delayed Price · Currency is CNY
20.86
+0.47 (2.31%)
Apr 22, 2025, 10:45 AM CST
6.37%
Market Cap 33.40B
Revenue (ttm) 25.56B
Net Income (ttm) 1.96B
Shares Out 1.61B
EPS (ttm) 1.19
PE Ratio 17.43
Forward PE 14.33
Dividend 0.30 (1.47%)
Ex-Dividend Date Oct 11, 2024
Volume 5,473,789
Average Volume 19,457,207
Open 20.67
Previous Close 20.39
Day's Range 20.67 - 21.09
52-Week Range 15.68 - 25.90
Beta 0.97
RSI 52.03
Earnings Date Apr 29, 2025

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection for endotracheal intubation, and general anesthesia using artificial respiration; remifentanil hydrochloride for Injection for induction and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients requiring opioid analgesia; nabuphine hydrochloride injection for induction of anesthesia; alfentanil hydrochloride injectio... [Read more]

Sector Healthcare
Founded 1993
Employees 17,676
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2023, SHA:600079's revenue was 24.52 billion, an increase of 9.79% compared to the previous year's 22.34 billion. Earnings were 2.13 billion, a decrease of -14.07%.

Financial Statements

News

There is no news available yet.